<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2393-6797</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Medicina Interna ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Urug. Med. Int.]]></abbrev-journal-title>
<issn>2393-6797</issn>
<publisher>
<publisher-name><![CDATA[Sociedad de Medicina Interna del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2393-67972025000101303</article-id>
<article-id pub-id-type="doi">10.26445/10.01.6</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Riesgo de fibrosis hepática por el Score FIB-4 en pacientes diabéticos con insuficiencia cardíaca. Subanálisis del estudio EMPUMIC]]></article-title>
<article-title xml:lang="en"><![CDATA[Risk of liver fibrosis due to the FIB-4 Score in diabetic patients with heart failure. Subanalysis of the EMPUMIC study]]></article-title>
<article-title xml:lang="pt"><![CDATA[Risco de fibrose hepática pelo escore FIB-4 em pacientes diabéticos com insuficiência cardíaca. Subanálise do estudo EMPUMIC]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Rojas]]></surname>
<given-names><![CDATA[Zulay Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ormaechea Gorricho]]></surname>
<given-names><![CDATA[Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de la República Facultad de Medicina. Unidad Académica Médica A. Unidad Multidisciplinaria de Insuficiencia Cardíaca (UMIC). Unidad Académica Médica A Hospital de Clínicas]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>10</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S2393-67972025000101303&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S2393-67972025000101303&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S2393-67972025000101303&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción: La esteatosis hepática metabólica (MASLD: Metabolic dysfunction-associated steatotic liver disease) es una entidad que abarca hígado graso, esteatohepatitis, fibrosis, cirrosis y carcinoma hepatocelular. Su prevalencia está en aumento asociado al incremento de diabetes mellitus 2 (DM2) y obesidad, siendo un problema de salud pública a nivel mundial. La prevalencia de MASLD es de un 55.5%, 37.3% esteatohepatitis, 17% fibrosis hepática. También es considerada una comorbilidad de la insuficiencia cardíaca (IC) con un comportamiento bidireccional por el compromiso sistémico de ambas patologías. Existen métodos no invasivos, que pueden identificar el riesgo de fibrosis hepática como el score FIB-4. Estudios han mostrado el beneficio de la empagliflozina en MASLD. Este trabajo tiene como objetivo determinar la prevalencia del riesgo de presentar fibrosis hepática mediante el score FIB-4 y evaluar los cambios de la categoría del riesgo al año de recibir dicho fármaco.  Metodología: El presente subanálisis del trabajo EMPUMIC &#8220;uso de empagliflozina en pacientes diabéticos con insuficiencia cardíaca con fracción de eyección reducida (ICFEr)&#8221;. Estudio retrospectivo, descriptivo, observacional de la población incluida en el estudio EMPUMIC, los datos fueron recolectados en Excel, se realizó el calculó del score FIB-4 que cuenta con cuatro variables como son, edad, transaminasas (AST/ALT) y plaquetas.  Resultados: Se incluyeron 31 pacientes (17 hombres) con edad mediana de 61 años. Se observó un descenso significativo de los niveles de transaminasas con el tratamiento con empagliflozina (p:0,015). El 74,19% de los pacientes antes de empezar tratamiento con empagliflozina presentan riesgo de fibrosis hepática por el score FIB-4 y al año de tratamiento con este fármaco presentó una reducción significativa del riesgo (p:0,049).  Conclusiones: Se observó un alto riesgo de desarrollar fibrosis hepática en pacientes con IC y DMT2. El tratamiento por un año con empagliflozina mostró un cambio en la categoría de riesgo por el score FIB-4 y disminución de los niveles de transaminasas. Es importante pesquisar esta comorbilidad tan prevalente para poder realizar una intervención oportuna.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction: Metabolic hepatic steatosis (MASLD: Metabolic dysfunction-associated steatotic liver disease) is an entity that includes fatty liver, steatohepatitis, fibrosis, cirrhosis and hepatic carcinoma. Its prevalence is increasing associated with the increase in diabetes mellitus 2 (DMT2) and obesity, being a public health problem worldwide. The prevalence of MASLD is 55.5%, 37.3% steatohepatitis, 17% hepatic fibrosis. It is also considered a comorbidity of heart failure (HF) with a bidirectional behavior due to the systemic involvement of both pathologies. There are noninvasive methods that can identify the risk of liver fibrosis such as the FIB-4 score. Studies have shown the benefit of empagliflozin in MASLD. This work aims to determine the prevalence of the risk of developing liver fibrosis using the FIB-4 score and evaluate the changes in the risk category one year after receiving said drug.  Methodology: This subanalysis of the EMPUMIC study &#8220;use of empagliflozin in diabetic patients with heart failure with reduced ejection fraction (HFrEF)&#8221;. Retrospective, descriptive, observational study of the population included in the EMPUMIC study. The data were collected in Excel, the FIB-4 score was calculated, which has four variables such as age, transaminases (AST/ALT) and platelets.  Results: 31 patients (17 men) with a median age of 61 years were included. A significant decrease in transaminase levels was observed with treatment with empagliflozin (p: 0.015). 74.19% of patients before starting treatment with empagliflozin were at risk of liver fibrosis due to the FIB-4 score and one year after treatment with this drug, there was a significant reduction in risk (p: 0.049).  Conclusions: A high risk of developing liver fibrosis was observed in patients with HF and DMT2. One-year treatment with empagliflozin showed a change in the risk category by the FIB-4 score and a decrease in transaminase levels. It is important to investigate this very prevalent comorbidity in order to carry out a timely intervention.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução: A esteatose hepática metabólica (MASLD: doença hepática esteatótica associada à disfunção metabólica) é uma entidade que inclui fígado gorduroso, esteatohepatite, fibrose, cirrose e carcinoma hepático. Sua prevalência vem aumentando associada ao aumento do diabetes mellitus 2 (DMT2) e da obesidade, sendo um problema de saúde pública mundial. A prevalência de MASLD é de 55,5%, esteatohepatite 37,3% e fibrose hepática 17%. Também é considerada uma comorbidade de insuficiência cardíaca (IC) com comportamento bidirecional devido ao envolvimento sistêmico de ambas as patologias. Existem métodos não invasivos que podem identificar o risco de fibrose hepática, como o escore FIB-4. Estudos demonstraram o benefício da empagliflozina no MASLD. Este trabalho tem como objetivo determinar a prevalência do risco de apresentar fibrose hepática através do escore FIB-4 e avaliar as alterações na categoria de risco um ano após o recebimento do referido medicamento.  Metodologia: A presente subanálise do trabalho EMPUMIC &#8220;uso de empagliflozina em pacientes diabéticos com insuficiência cardíaca com fração de ejeção reduzida (ICFEr)&#8221;. Estudo retrospectivo, descritivo, observacional da população incluída no estudo EMPUMIC, os dados foram coletados em Excel, foi calculado o escore FIB-4, que possui quatro variáveis &#8203;&#8203;como idade, transaminases (AST/ALT) e plaquetas.  Resultados: Foram incluídos 31 pacientes (17 homens) com idade mediana de 61 anos. Foi observada diminuição significativa nos níveis de transaminases com o tratamento com empagliflozina (p:0,015). Antes de iniciar o tratamento com empagliflozina, 74,19% dos pacientes apresentavam risco de fibrose hepática com base no escore FIB-4 e após um ano de tratamento com este medicamento houve redução significativa do risco (p:0,049).  Conclusões: Foi observado alto risco de desenvolver fibrose hepática em pacientes com IC e DMT2. O tratamento durante um ano com empagliflozina demonstrou alteração da categoria de risco para o escore FIB-4 e diminuição dos níveis de transaminases. É importante investigar esta comorbidade altamente prevalente para realizar uma intervenção oportuna.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[insuficiencia cardíaca]]></kwd>
<kwd lng="es"><![CDATA[fibrosis hepática]]></kwd>
<kwd lng="es"><![CDATA[empaglifozina]]></kwd>
<kwd lng="en"><![CDATA[heart failure]]></kwd>
<kwd lng="en"><![CDATA[liver fibrosis]]></kwd>
<kwd lng="en"><![CDATA[empagliflozin]]></kwd>
<kwd lng="pt"><![CDATA[insuficiência cardíaca]]></kwd>
<kwd lng="pt"><![CDATA[fibrose hepática]]></kwd>
<kwd lng="pt"><![CDATA[empagliflozina]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eslam]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Newsome]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Sarin]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Anstee]]></surname>
<given-names><![CDATA[QM]]></given-names>
</name>
<name>
<surname><![CDATA[Targher]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Romero-Gomez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A new definition for metabolic dysfunction-associated fatty liver disease An international expert consensus statement]]></article-title>
<source><![CDATA[J Hepatol]]></source>
<year>2020</year>
<volume>73</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>202-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Koh]]></surname>
<given-names><![CDATA[TJL]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[ASP]]></given-names>
</name>
<name>
<surname><![CDATA[Quek]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yong]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Tay]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease A Meta-Analysis and Systematic Review of 10 739 607 Individuals]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2022</year>
<volume>107</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2691-700</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ayada]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults]]></article-title>
<source><![CDATA[Clin Gastroenterol Hepatol]]></source>
<year>2022</year>
<volume>20</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>e573-82</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcia]]></surname>
</name>
</person-group>
<collab>Z.Olaya Q.Silva M.Ormaechea G.Evaluación de riesgo de fibrosis hepática en pacientes con diabetes mellitus por el FIB-4</collab>
<source><![CDATA[Semana Académica 2024]]></source>
<year>2024</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[Hospital de Clínicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pipitone]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Ciccioli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Infantino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[La Mantia]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Parisi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tulone]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MAFLD a multisystem disease]]></article-title>
<source><![CDATA[Ther Adv Endocrinol Metab]]></source>
<year>2023</year>
<volume>14</volume>
<page-range>20420188221145549</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pedley]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Massaro]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffmann]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bi-directional analysis between fatty liver and cardiovascular disease risk factors]]></article-title>
<source><![CDATA[J Hepatol]]></source>
<year>2017</year>
<volume>66</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>390-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonapace]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Perseghin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Molon]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Canali]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bertolini]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zoppini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2012</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>389-95</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<collab>European Association for the Study of the Liver</collab>
<article-title xml:lang=""><![CDATA[EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update]]></article-title>
<source><![CDATA[J Hepatol]]></source>
<year>2021</year>
<volume>75</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>659-89</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<collab>European Association for the Study of the Liver.European Association for the Study of Diabetes.European Association for the Study of Obesity</collab>
<article-title xml:lang=""><![CDATA[Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)]]></article-title>
<source><![CDATA[J Hepatol]]></source>
<year>2024</year>
<volume>81</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>492-542</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association Professional Practice Committee</collab>
<article-title xml:lang=""><![CDATA[4 Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2024]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2024</year>
<volume>47</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S52-76</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivadeneira Poveda]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Jurado Melo]]></surname>
<given-names><![CDATA[VC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Updated diagnosis, treatment and complications of the fatty liver disease]]></article-title>
<source><![CDATA[Anatomía Digital]]></source>
<year>2023</year>
<volume>6</volume>
<numero>1.2</numero>
<issue>1.2</issue>
<page-range>6-29</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McPherson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hardy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dufour]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Petta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Romero-Gomez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Allison]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2017</year>
<volume>112</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>740-51</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Filozof]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Liver Fibrosis as Assessed by the FIB-4 Index in Patients with Type 2 Diabetes (T2DM)]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2018</year>
<volume>67</volume>
<numero>^sSupp. 1</numero>
<issue>^sSupp. 1</issue>
<supplement>Supp. 1</supplement>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ouzan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mosnier]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Penaranda]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Daviaud]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Joly]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Muntlak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prospective screening for significant liver fibrosis by fibrosis-4 in primary care patients without known liver disease]]></article-title>
<source><![CDATA[Eur J Gastroenterol Hepatol]]></source>
<year>2021</year>
<volume>33</volume>
<numero>1S Suppl 1</numero>
<issue>1S Suppl 1</issue>
<page-range>e986-91</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vali]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Boursier]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Spijker]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Anstee]]></surname>
<given-names><![CDATA[QM]]></given-names>
</name>
<name>
<surname><![CDATA[Bossuyt]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events A systematic review]]></article-title>
<source><![CDATA[Liver Int]]></source>
<year>2021</year>
<volume>41</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>261-70</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Genua]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Iruzubieta]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Duque]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Crespo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NAFLD and type 2 diabetes A practical guide for the joint management]]></article-title>
<source><![CDATA[Gastroenterol Hepatol]]></source>
<year>2023</year>
<volume>46</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>815-25</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taheri]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Malek]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ismail-Beigi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Zamani]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Sohrabi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Reza Babaei]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes A Randomized, Double-Blind, Placebo-Controlled Trial]]></article-title>
<source><![CDATA[Adv Ther]]></source>
<year>2020</year>
<volume>37</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>4697-708</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Mok]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists]]></article-title>
<source><![CDATA[J Obes Metab Syndr]]></source>
<year>2019</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>18-29</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kahl]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gancheva]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial]]></article-title>
<collab>Straßburger K.Herder C.Machann J.Katsuyama H</collab>
<source><![CDATA[Diabetes Care]]></source>
<year>2020</year>
<volume>43</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>298-305</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Rojas]]></surname>
<given-names><![CDATA[ZA]]></given-names>
</name>
<name>
<surname><![CDATA[Cristancho Sierra]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Peréz Papadópulos]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Ormaechea Gorricho]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso de empagliflozina en pacientes diabéticos tipo 2 con insuficiencia cardíaca]]></article-title>
<source><![CDATA[Rev Urug Med. Interna]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prieto-Ortiz]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Luque]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Ortega-Quiroz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hígado graso (parte 2) enfoque clínico y tratamiento]]></article-title>
<source><![CDATA[Rev. colomb]]></source>
<year>2023</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>46-58</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lai L-L]]></surname>
</name>
<name>
<surname><![CDATA[Vethakkan]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Mustapha]]></surname>
<given-names><![CDATA[NRN]]></given-names>
</name>
<name>
<surname><![CDATA[Mahadeva]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chan W-K]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Dig Dis Sci]]></source>
<year>2020</year>
<volume>65</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>623</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shimizu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Jojima]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Iijima]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Murohisa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease]]></article-title>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2019</year>
<volume>21</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>285-92</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leiter]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Forst]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Polidori]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Balis]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sha]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of canagliflozin on liver function tests in patients with type 2 diabetes]]></article-title>
<source><![CDATA[Diabetes Metab]]></source>
<year>2016</year>
<volume>42</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-32</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Shimizu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Inoue]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Saito]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Yanagisawa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Inukai]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2Diabetes A Randomized, 24-Week, Open-Label, Active-Controlled Trial]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2017</year>
<volume>40</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1364-72</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Katsuyama]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hamasaki]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Adachi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Moriyama]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kawaguchi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sako]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes a Chart-Based Analysis]]></article-title>
<source><![CDATA[J Clin Med Res]]></source>
<year>2016</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>237-43</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pallarés]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Escobar]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Egocheaga]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Obaya]]></surname>
<given-names><![CDATA[J.C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impacto de dapagliflozina en los factores de riesgo cardiovascular: más allá del control de la glucemia]]></article-title>
<source><![CDATA[Medicina de Familia. SEMERGEN]]></source>
<year>2021</year>
<volume>47</volume>
<numero>^sSupp 1</numero>
<issue>^sSupp 1</issue>
<supplement>Supp 1</supplement>
<page-range>1-4</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
